OLDWICK, N.J., Jan. 28, 2019 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company
dedicated to developing novel therapeutics aimed at intercepting
and preventing immune-mediated diseases, announced today that it
has received a Notice of Allowance from the United States Patent
and Trademark Office (USPTO) for its patent application titled,
"Multi-CBV Vaccine for Preventing or Treating Type 1 Diabetes."
The patent application covers methods of use involving the
development of a coxsackievirus B (CVB) vaccine for the prevention
and/or treatment of type 1 diabetes (T1D).
![(PRNewsfoto/Provention Bio, Inc.) (PRNewsfoto/Provention Bio, Inc.)](https://mma.prnewswire.com/media/720849/Provention_Bio_Logo.jpg)
Provention Bio is developing PRV-101 as a vaccine for acute
coxsackie virus infection and potentially as the first-ever vaccine
designed to prevent T1D. Epidemiological and experimental
studies indicate that approximately half of all T1D cases could be
triggered by a CVB infection in early childhood. Based on
this research, which was recently the subject of a peer-reviewed
paper in Expert Review of Vaccines (Developing a Vaccine
for Type 1 Diabetes by Targeting Coxsackievirus B), Provention
Bio is developing PRV-101 to reduce the onset of T1D by vaccinating
at-risk populations against CVB infection. PRV-101 is
currently in an IND-enabling stage prior to initiation of
first-in-human studies.
"This Notice of Allowance from the USPTO is a significant
advancement in the ongoing development of PRV-101 and emboldens
Provention's vision to develop a vaccine for CVB that could
potentially prevent up to 50% of worldwide T1D cases," said
Ashleigh Palmer, Provention Bio's
Co-Founder and Chief Executive Officer. "As we advance
PRV-101 towards the clinic, we will continue to aggressively pursue
opportunities to strengthen the intellectual property estate
surrounding this technology and the use of a polyvalent CVB vaccine
to prevent
T1D."
About Provention Bio, Inc.
Provention Bio, Inc.
(Nasdaq: PRVB) is a clinical-stage biopharmaceutical company
leveraging a transformational drug development strategy that is
focused on the prevention or interception of immune-mediated
disease. Provention's mission is to in-license, transform and
develop therapeutic candidates targeting the high morbidity,
mortality and escalating costs of autoimmune and inflammatory
diseases including: type 1 diabetes (T1D), Crohn's disease,
ulcerative colitis, celiac disease, lupus, and certain
life-threatening viral diseases. Provention's diversified portfolio
includes advanced-stage product development candidates that have
undergone clinical testing by other companies. For more information
on Provention Bio, please visit www.proventionbio.com.
Forward Looking Statements
Certain statements in
this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimate," "expect," and
"intend," among others. These forward-looking statements are based
on Provention's current expectations and actual results could
differ materially. There are a number of factors that
could cause actual events to differ materially from those indicated
by such forward-looking statements. These factors include, but are
not limited to, risks related to failure to obtain FDA approvals or
clearances and noncompliance with FDA regulations; uncertainties of
patent protection and litigation; limited research and development
efforts and dependence upon third parties; substantial competition;
our need for additional financing and the risks listed under "Risk
factors" in our quarterly report on Form 10-Q for the quarter ended
September 30, 2018 and any subsequent
filings with the Securities and Exchange Commission (SEC). As with
any pharmaceutical under development, there are significant risks
in the development, regulatory approval and commercialization of
new products. Provention does not undertake an obligation to update
or revise any forward-looking statement. The information set forth
herein speaks only as of the date hereof.
Media & Investor Contacts
Jason Rando / Joshua
Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
T: 212 375 2665 / 212 375 2664
jrando@tiberend.com
jdrumm@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-receives-notice-of-allowance-from-united-states-patent-and-trademark-office-for-patent-on-multi-strain-coxsackievirus-b-vaccine-for-preventing-or-treating-type-1-diabetes-t1d-300784878.html
SOURCE Provention Bio, Inc.